Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor Combo for EBV-Associated Diseases
NCT07133776Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Sep 2025
- Primary completion
- Sep 2027
01
Overview
Phase 2, open-label, single-arm trial in Epstein-Barr virus infection, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Overall Response Rate at 3 months. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07133776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133776.